At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Sapanisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
In Brief
A Phase 2 clinical trial evaluating Sapanisertib for Pancreatic Neuroendocrine Tumor G1 and 2 related conditions. Completed, enrolled 13 participants across 405 sites.
Detailed Summary
This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartApr 2017
Primary CompletionMay 2021
Study CompletionDec 2022
TodayJul 2026
First PostedSep 9, 2016
Enrollment StartApr 28, 2017
Primary CompletionMay 11, 2021
Study CompletionDec 21, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 9.8 years ago
Interventions
Sapanisertibdrug
Given PO